Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10484395 | 0.90 | TAAR1 (0.58) | TAAR1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL5242878 | 0.89 | SMN1; SMN2 (0.50) | TAAR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22067943 | 0.89 | TAAR1 (0.50) | TAAR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10484340 | 0.88 | TAAR1 (0.56) | TAAR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13290402 | 0.86 | TAAR1 (0.50) | TAAR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7904758 | 0.86 | SIGMAR1 (0.53) | TAAR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL11922708 | 0.82 | KMT2A (0.59) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL20689749 | 0.82 | MAOB (0.57) | TAAR1NPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL4095146 | 0.80 | TAAR1 (0.44) | TAAR1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL10962630 | 0.80 | MAOB (0.59) | TAAR1NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| US-20220315961-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-10-06 | — | — | US | disclosed |
| US-11377673-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11352609-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210301266-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-09-30 | — | — | US | disclosed |
| US-11060072-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10947572-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20150132807-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-05-14 | — | — | US | disclosed |
| US-20150132807-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-05-14 | — | — | US | disclosed |
| US-20130302859-A1 | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds. | CODEXIS,INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302859-A1 | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds. | CODEXIS,INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2010035111-A1 | A PROCESS FOR THE PREPARATION OF ROTIGOTINE | FIDIA FARMACEUTICI S.P.A. (IT) | 2010-04-01 | — | — | WO | disclosed |
| WO-2009063170-A1 | PREPARATION OF CRYSTALLINE ROTIGOTINE BASE | PLIVA HRVATSKA D.O.O. (HR) | 2009-05-22 | — | — | WO | disclosed |
| EP-1091946-B1 | NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE | WIKSTROEM HAKAN VILHELM (NL) | 2004-03-17 | — | — | EP | disclosed |
| US-6291494-B1 | 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use | ASTRAZENECA AB (SE) | 2001-09-18 | — | — | US | disclosed |
| EP-1091946-A1 | NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE | WIKSTRÖM, Hakan Vilhelm (NL) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001680-A1 | NEW 2-AMINOTHIAZOL-FUSED 2-AMINOINDANS AND 2-AMINOTETRALINS AND THEIR USE | WIKSTROEM HAKAN VILHELM (NL) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352609-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | TAAR1 517/4885NPC1 3962/4885RAB9A 4226/4885 |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | TAAR1 517/4885NPC1 3962/4885RAB9A 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.